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ABSTRACT 
Objective: The main objective of this study was to investigate the degradation products (DPs) of Etodolac (ETD) API under different stress 
conditions (acid hydrolysis, base hydrolysis, oxidation, thermal and photolysis) and to characterize the major DPs using Liquid Chromatography-
tandem Mass Spectrometry (LC-MS/MS) and Infrared (IR) spectroscopy.  
Methods: The proposed study describes a reversed-phase LC and LC-MS/MS method. Separation of ETD and its DPs was achieved on a Phenomenex 
C18 column. Structures of the major DPs were studied using a Triple Quadrupole Mass Spectrometer. A separate gradient LC-MS/MS method was 
developed for this purpose. The analysis was done using Shim-pack XR ODS column. Possible chemical reactions were predicted depending on the 
degradation type and the fragmentation data obtained from LC-MS/MS. Major DPs were isolated using preparative LC technique. These DPs were 
obtained in solid form using rotavap and lyophilizer and were then analyzed by IR spectroscopy to confirm their structural details. 
Results: ETD was found to degrade completely under acid hydrolysis; it degraded 68 % under oxidation, 25 % after photolysis, 6 % in basic 
conditions and less than 1 % in thermal degradation. Four major DPs were characterized using LC-MS/MS and IR spectroscopy. 
Conclusion: The DPs of ETD were investigated and characterized. Also, the tentative degradation pathways of ETD under different stress conditions 
were postulated. 
Keywords: Etodolac, Forced degradation studies, Degradation products, LC, LC-MS/MS  
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INTRODUCTION 
ETD, (RS)-2-(1, 8-Diethyl-4, 9-dihydro-3H-pyrano [3, 4-b] indol-1-yl) 
acetic acid is a non-steroidal anti-inflammatory drug (NSAID). This 
group of drugs has anti-inflammatory, analgesic and antipyretic 
activities. ETD is used worldwide to relieve inflammation, swelling, 
stiffness and joint pain in conditions like osteoarthritis and 
rheumatoid arthritis, as well as for general pain relief [1-3].  
Forced degradation (FD) is a process whereby the natural 
degradation rate of a drug product or drug substance is accelerated 
by the application of an additional stress. FD studies or stress testing 
form a very important part of the drug development strategy in 
pharmaceutical industries under the guidelines of International 
Conference on Harmonization (ICH) and is carried out under more 
severe conditions than accelerated conditions [4]. The purpose of 
stress testing is to provide evidence on how the quality of a drug 
substance or drug product varies with time under the influence of a 
variety of environmental factors such as temperature, humidity, 
light, etc. These studies serve to give information on a drug’s 
inherent stability and assist in the validation of analytical methods 
to be used in stability studies. It also helps in determining the DPs and 
in estimating the tentative degradation pathway of the drug. 
Identification and qualification of these DPs is quite essential since it 
can cause undesirable side effects in patients, at times these side 
effects could also be fatal. Hence even though ICH and Food and Drug 
Administration (FDA) asks to include this study at Phase III of the 
clinical trial, it is recommended to start it as early as possible [5-12]. 
For the proposed study, ETD API (fig. 1) was subjected to 
degradation under different stress conditions like acid hydrolysis, 
base hydrolysis, oxidation, thermal and photolysis. Generally, during 
method development in pharmaceutical industries, a drug molecule 
is subjected to a maximum of 5-20 % degradation which is enough 
to provide a brief idea about its likely DPs [13, 14]. However, more 
harsh conditions were used in the present study to achieve complete 
or near to complete degradation of the drug substance so as to 
obtain a better indication of the DPs that are formed after maximum 
degradation and also to acquire relevant information regarding the 
degradation pathway of the molecule. Thus, the main purpose of this 
study was to identify and characterize the DPs formed after 
complete or maximum degradation of ETD, under different stress 
conditions using LC-MS/MS and IR spectroscopy techniques. A 
gradient LC method was developed for separation of ETD and its DPs. 
Simultaneously, a LC-MS/MS method was also developed to identify 
the DPs. An isocratic LC method was used on preparative LC to isolate 
the major DPs (which were found to be present ≥ 10 %). The fractions 
of DPs collected from preparative LC were processed through rotavap 
to evaporate the organic modifiers followed by lyophilization in order 
to obtain the DPs in solid form. IR spectra of these DPs were then 
obtained as a supporting data to LC-MS/MS results. 
Literature survey revealed various analytical methods for the 
determination of ETD and few stability indicating assay methods. 
These included HPTLC [15-17], UV-Vis Spectrophotometry [18-23], 
RP-HPLC [24, 25], RP-UPLC [26] and a LC-MS method [27]. But, so 
far no detailed study on the DPs of ETD has been reported, especially 
using LC-MS/MS, to the best of our knowledge. Therefore, the 
present work was undertaken with the objective of developing a LC 
and LC-MS/MS method for studying the major DPs of ETD, to obtain 
the masses and the fragmentation pattern of these DPs formed after 
maximum degradation of the drug molecule and also to elucidate the 
tentative degradation pathway of ETD under different stress 
conditions, based on the MS and IR data. Thus, the novel 
contribution of this research paper was to investigate the DPs of 
ETD which are not yet reported, using LC-MS/MS and IR techniques. 
 
Fig. 1: Chemical structure of etodolac 
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MATERIALS AND METHODS 
Chemicals and reagents 
ETD API was procured from Hetero Chemical Lab (Hyderabad, 
India) with a purity of 99.4 % w/w. 
HPLC grade-Acetonitrile, Formic acid, water; Analytical grade-
Hydrochloric acid (HCl), Sodium Hydroxide (NaOH), Hydrogen 
Peroxide (H2O2)–30 % v/v and LC-MS grade-Formic acid were 
purchased from Merck (Mumbai, India). 
Sample preparation 
ICH guidelines were referred for carrying out forced degradation 
studies [4, 28]. Since the aim was to obtain maximum degradation of 
the molecule, the conditions were modified accordingly. 
(A) For LC and LC-MS/MS analysis 
Diluent 
Water: ACN (1:1, v/v)  
Blank 
Diluent was used as blank 
Standard 
12.5 mg of ETD API was weighed and transferred to 25 ml volumetric 
flask; dissolved and volume made up with the diluent (500 ppm). 
Acid degradation 
12.5 mg of ETD API was weighed in a 25 ml volumetric flask. To this 5.0 
ml of the diluent was added to dissolve the API followed by 5.0 ml of 5 M 
HCl. The solution was kept in water bath at 60 °C for 8 h; it was then 
cooled at room temperature, neutralized with 5 M NaOH and volume 
was made up with the diluent (500 ppm). This solution was filtered 
through 0.45 µ Millipore membrane before injecting into the system. 
Blank was given the same treatment as that of the sample. 
Alkali degradation 
12.5 mg of ETD API was weighed in a 25 ml volumetric flask. To this 
5.0 ml of the diluent was added to dissolve the API followed by 5.0 
ml of 5 M NaOH. The solution was kept in water bath at 80 °C for 8 h; 
it was then cooled at room temperature, neutralized with 5 M HCl 
and volume was made up with the diluent (500 ppm). This solution 
was filtered through 0.45 µ Millipore membrane before injecting 
into the system. 
Blank was given the same treatment as that of the sample. 
Oxidative degradation 
12.5 mg of ETD API was weighed in a 25 ml volumetric flask. To this 
5.0 ml of the diluent was added to dissolve the API followed by 5.0 
ml of 30 % H2O2 (v/v). The solution was kept in water bath at 80 °C 
for 8 h. It was cooled at room temperature and volume was made up 
with the diluent (500 ppm). This solution was filtered through 0.45 
µ Millipore membrane before injecting into the system. 
Blank was given the same treatment as that of the sample. 
Thermal degradation 
100 mg of ETD API was kept in controlled oven at 105 °C for 7 d. 
From this, 12.5 mg of the API was weighed in a 25 ml volumetric 
flask, dissolved and volume made up with the diluent (500 ppm). 
This solution was filtered through 0.45 µ Millipore membrane before 
injecting into the system. 
Photolysis 
12.5 mg of ETD API was weighed in a 25 ml volumetric flask, 
dissolved and volume made up with the diluent. This solution was 
exposed to UV radiation for 1.2 million Lux hours. It was filtered 
through 0.45 µ Millipore membrane before injecting onto the 
system. 
(B) Preparative LC 
Acid degradation 
1 g of ETD API was weighed and dissolved in 15.0 ml of the diluent, 
to this 5.0 ml of 5 M HCl was added. The solution was kept in water 
bath at 60 °C for 8 h; it was then cooled at room temperature and 
neutralized with 5 M NaOH. This was filtered through 0.45 µ 
Millipore membrane before injecting into the system. 
Oxidation degradation 
1 g of ETD API was weighed and dissolved in 15.0 ml of the diluent, 
to this 5.0 ml of 30 % H2O2 (v/v) was added. The solution was kept 
in water bath at 80 °C for 8 h; it was then cooled at room 
temperature. This was filtered through 0.45 µ Millipore membrane 
before injecting into the system. 
LC analysis 
HPLC (Shimadzu Prominence Binary Gradient System, Shimadzu 
Corporation, Japan) equipped with a binary pump (20 AP), degasser, 
an autosampler (SIL-20AC), a temperature controlled column 
compartment and photodiode array detector (SPD-20A) was used. 
Chromatographic data was acquired using Lab solutions software. 
The analysis was done using Phenomenex C18 column (250 mm x 
4.6 mm, 5 µ). The mobile phase comprised of-(A) water (pH 3.0 
adjusted with formic acid) (B) acetonitrile, in a gradient mode. The 
gradient program is given in table 1. The flow rate was maintained 
at 1.5 ml/min; injection volume was 20 µl and the column 
temperature was maintained at 30 °C. Run time for the analysis was 
kept 32 min. The chromatograms were monitored at 225 nm. 
LC-MS/MS analysis 
HPLC system (Shimadzu Prominence Binary Gradient System, 
Shimadzu Corporation, Japan) equipped with a binary pump (LC-
30AD), autosampler (SIL-30ACMP), a temperature controlled 
column compartment (CTO-30A) and photodiode array detector 
(SPD-M20A) was used. Chromatographic data was acquired using 
Lab solutions software. The analysis was done using Shim-pack XR 
ODS column (100 mm x 2 mm, 3 µ). The mobile phase comprised of-
(A) water (pH 3.0 adjusted with formic acid) (B) acetonitrile, in a 
gradient mode. The gradient program is given in table 2. The flow 
rate was maintained at 0.4 ml/min; injection volume was 5 µl and 
the column temperature was maintained at 40 °C. Run time for the 
analysis was kept 10 min. The chromatograms were monitored at 
225 nm. The structure elucidation of DPs was done using triple 
quadrupole mass spectrometer LCMS-8040 equipped with the 
electrospray ionization (ESI) source, operated in positive mode. 
Nitrogen gas was used at flow rates of 2 l/min for nebulization, 15 
l/min for heating and as a curtain gas at 2.4 l/min. Argon was used 
as a collision gas. The collision energy was optimized and set to-30.0 
V. Mass spectra were acquired over m/z range of 100-300. Event 
time was off 0.03 seconds. 
 
Table 1: Gradient program used for liquid chromatography analysis 
Time A (%) B (%) 
0.01 50 50 
14.0 50 50 
22.0 30 70 
25.0 30 70 
27.0 50 50 
32.0 50 50 
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Table 2: Gradient program used for liquid chromatography-tandem mass spectrometry 
Time A (%) B (%) 
0.01 80 20 
5.00 10 90 
7.00 10 90 
7.10 80 20 
10.0 80 20 
 
Preparative LC analysis 
HPLC (Shimadzu Prominence Binary Gradient System, Shimadzu 
Corporation, Japan) equipped with binary pump (20 AP), degasser, 
injector (SIL-10AP), fraction collector (FRC 10A) and photodiode 
array detector (SPD-20A) was used. Chromatographic data was 
acquired using Lab solutions software. Analysis was done using 
Phenomenex C18 column (250 mm x 21 mm, 5 µ). The mobile phase 
comprised of-(A) water (pH 3.0 adjusted with formic acid) (B) 
acetonitrile (1:1, v/v). The flow rate was maintained at 30.0 ml/min; 
injection volume was 2.0 ml and column was maintained at room 
temperature (around 25 °C). The chromatograms were monitored at 
225 nm. 
IR analysis 
IR analysis was performed on 'IR Affinity-1' instrument with 
diamond ATR accessory, manufactured by Shimadzu, Shimadzu 
Corporation, Japan. 
RESULTS AND DISCUSSION 
The main objective of this study was to investigate the DPs of ETD 
under different stress conditions. For this purpose, ETD was 
subjected to base hydrolysis, acid hydrolysis, oxidation, thermal and 
photolytic degradation. ETD was found to degrade completely under 
acidic conditions; it degraded 6 % under basic conditions, 68 % 
under oxidative conditions, 25 % after photolysis and less than 1 % 
under thermal stress conditions.  
The results indicated that ETD is most degradable under acidic 
conditions followed by oxidative and photolytic conditions while it is 
most stable under thermal conditions followed by basic conditions. 
The degradation conditions and amount of degradation obtained are 
mentioned in table 3. Few degradation studies of ETD have been 
carried out in the past at much milder conditions than mentioned in 
this study; however no specific DPs were obtained or identified [29-
31]. A complete, similar degradation study of ETD has not been 
reported in the literature as yet. 
A gradient LC method was developed and optimized for 
separation of ETD and its DPs (table 1). There were two major 
DPs obtained under acid hydrolysis at a retention time (RT) of 
4.4 min and 23.8 min, one major DP under oxidative hydrolysis 
at 3.5 min, two major DPs under photolysis at 2.9 min and 3.6 
min; while there were no major DPs obtained under base 
hydrolysis and thermal degradation. The RT of ETD in this 
method was found to be around 11 min. The representative 
chromatograms are given in fig. 2. 
 
Table 3: Percentage of degradation observed in each of the stress conditions 
Degradation type Degradation condition Amount degraded (%) 
Acid hydrolysis 5 M HCl, 60 ⁰C, 8 h 100.00  
Base hydrolysis 5 M NaOH, 80 ⁰C, 8 h 5.74 
Oxidation 30 % H2O2, 80 ⁰C, 8 h 68.22 
Photolysis 1.2 million Lux h 24.73 
Thermal 105 °C, 7 d 0.70 
 
 
Fig. 2 (a) 
 
 
Fig. 2 (b) 
 
Fig. 2 (c) 
 
 
Fig. 2 (d) 
Saxena et al. 




Fig. 2 (e) 
 
 
Fig. 2 (f) 
Where, B=blank; Numbers= degradation products obtained 
under each stress conditions; Encircled peaks= peaks that were 
isolated on preparative liquid chromatography 
Fig. 2: Representative chromatograms of forced degradation 
study (a) etodolac (b) acid degradation (c) base degradation (d) 
oxidation degradation (e) thermal degradation (f) photolysis 
 
The major DPs of acid hydrolysis and oxidative hydrolysis were 
isolated using preparative LC technique. From the fractions 
collected, organic modifiers were distilled out using rotavap and 
water was removed by lyophilization techniques to obtain the DPs 
in solid form. The yield of DPs obtained after lyophilization was 
very less. Also, no product was obtained for the second DP of acid 
degradation (RT 23.8 min), and so it was not possible to perform 
its IR. The reason for not obtaining any product for this DP could 
be its instability. IR analysis of the remaining two DPs was 
performed. 
A separate gradient LC method (table 2) was also developed for 
analyzing the degradation samples of ETD and its isolated DPs on 
LC-MS/MS. The molecular weight of ETD is 287 and that of the 
protonated ion in the positive ion mode is 288. The masses of the 
major DPs obtained for acid degradation were m/z 190 and m/z 
244, oxidation degradation-m/z 304 and photolysis-m/z 304 and 
m/z 320. The DP with m/z of 304 was common in oxidation and 
photolysis. These major DPs were further subjected to product ion 
scan at different collision energies. 
 
 
(A-i) m/z 190 
 
(A-ii) m/z 244 
 
 
(B-i) m/z 304 
 
 
(C-i) m/z 320 
 
 
(C-ii) m/z 304 
Fig. 3: Product ion scan of major degradation products of etodolac 
obtained under different stress conditions (A) acid degradation: (i) 
m/z-190 (ii) m/z 244 (B) oxidation degradation: (i) m/z-304 (C) 
photolysis: (i) m/z–320 (ii) m/z 304 
 
Best fragmentation was obtained at collision energy of-30.0V. The 
production scan of the major DPs of ETD under different stress 
conditions is given in fig.3; while table 4 shows the precursor ions 
and their respective product ion scan. The acid DPs of ETD have 
been reported in two similar studies [32, 33]. The masses of both the 
acid DPs are also specified in one of the study [32] and are in 
agreement with the present study. The other DPs obtained in the 
present study are not reported in the literature. So far, no other 
study has provided the masses and fragmentation pattern of the DPs 
of ETD. 
Saxena et al. 
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Table 4: Precursor ions and their respective product ion scan obtained from liquid chromatography-tandem mass spectrometry study 
Stress conditions Precursor ions (m/z) Collision energy used product ion scan obtained (m/z) 
Acid 190 -30 V 117,143,157,172 
244 131,143,158,168,170,182,196,210 
Oxidation 304 132,142,160,170,188,216,244 
Photolysis 304 117,132,142,160,170,188,216,244 
320 134,148,158,174,176,204 
 
Structural elucidation of the DPs and the tentative degradation 
pathway of ETD (fig.4) were predicted based on the fragmentation 
pattern of the DPs and the type of degradation. The neutral losses of 
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Fig. 4: Tentative degradation pathway of etodolac under different stress conditions, based on the degradation type and the fragmentation 
pattern of the degradation products obtained by mass spectrometry data (A) acid (B) oxidation(C) photolysis 
 
Table 5: Neutral losses for the degradation pathways of etodolac 
Degradation 
type 
m/z of major degradation products (precursor ions) and their 
*mass difference (neutral loss/gain) 
m/z of product ion scan and their #neutral loss 
Acid 190 (C12H15NO) 
Neutral loss of 98 units (C5H6O2) 
143 (C10H10N•) 
Neutral loss of 45 units (C2H5O•) 
157 (C11H12N•)  
Neutral loss of 31 units (CH3O•) 
172 (C12H14N•)  
Neutral loss of 17 units (•OH) 
244 (C16H21NO) 
Neutral loss of 44 units(CO2) 
143 (C10H9N••) 
Neutral loss of 100 units (C6H12O••) 
168 (C10H17NO)  
Neutral loss of 76 units (C6H4) 
182 (C11H19NO)  
Neutral loss of 62 units (C5H2) 
Oxidation 304 (C17H21NO4) 
Neutral gain of 16 units (O••) 
132 (C6H12O3)  
Neutral loss of 172 units (C11H9NO••) 
160 (C10H9NO••)  
Neutral loss of 144 units (C7H12O3••) 
188 (C12H13NO••)  
Neutral loss of 116 units (C5H8O3••) 
Photolysis 320 (C17H21NO5) 
Neutral gain of 32 units(2O••) 
148 (C9H9NO)  
Neutral loss of 172 units (C8H12O4) 
158 (C10H7NO••)  
Neutral loss of 162 units (C7H14O4••) 
176 (C10H9NO2••) 
Neutral loss of 144 units (C7H12O3••) 
304 
(as mentioned under the oxidative condition) 
Productions and neutral loss–same as mentioned 
under the oxidative condition) 
* Mass difference w. r. t. t parent drug molecule (m/z 288), #Neutral loss w. r. t. t corresponding precursor ions 
 
The major functional groups of the DPs were also specified in IR 
analysis. The main frequencies of IR which support the 
inferences drawn from the MS/MS data are: presence of 1720.5 
band representing C= O group and absence of the–NH group, in 
the oxidation DP (m/z 304); presence of 3394.7 band 
representing–NH group and absence of C=O group, in the acid DP 
(m/z 190). The IR spectra are given in fig.5 and their 
interpretations in table 6.  
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Fig. 5: Infrared spectra of (a) etodolac (b) oxidation degradation product (m/z 304) (c) acid degradation product (m/z 190) 
 
Table 6: Interpretation for infrared spectroscopy 
(A) Oxidation degradation product (m/z–304) 
S. No. Frequency range Actual band obtained Functional group 
1) 1700-1720 S 1720.5 C=O 
2a) 1210-1310 S 1220.9, 1253.7, 1286.5,1309.6 C-O-C 
2b) 1010-1050 M 1022.27 
2c) 1170-1250 S 1192.0, 1220.9 
3a) 2500-3100 2833.4, 2897.0,2937.6, 2972.3,3068.8 -OH 
3b) 875-960 M 879.5 
 
 (B) Acid degradation product (m/z–190) 
S. No. Frequency range Actual band obtained Functional group 
1) 3100-3400 3394.7 Pyrole (-H bonded) 
2) 3400(Approx.) M 3394.7 Aromatic secondary Amine (ArNHR) 
3a) 2500-3100 S 2866.2, 2926.0, 2962.6 -OH 
3b) 1280-1380 M 1321.2, 1340.5 
Saxena et al. 
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The IR spectra of ETD in its pure as well as in combined form (along 
with other drugs and excipients) are available in the literature [34, 
35]; however, the IR spectra of the DPs are not yet reported. 
In the future, a larger amount of DPs can be isolated on preparative 
LC and NMR analysis can be performed for an additional 
confirmation of structures. 
CONCLUSION 
From the stress studies carried out, it was found that ETD is highly 
degradable under acidic conditions (100 %), followed by oxidative 
(68 %) and photolytic conditions (25 %); while it’s most stable 
under the thermal conditions (<1 %) followed by the basic 
conditions (6 %). 
A simple gradient LC method was successfully developed and 
optimized for the separation of ETD and its DPs. Also, a fast LC-MS/MS 
method was effectively developed to identify the DPs; being a fast 
method, it saves lot of time and resources. The study was helpful in 
characterizing four major DPs of ETD-based on the LC-MS/MS and IR 
data. The masses of these major DPs of ETD were found to be: acid-
190 and 244; oxidation-304, photolysis-304 and 320. 
A tentative degradation pathway of ETD was also postulated under 
different chemical stress conditions. 
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